Humana Inc (HUM) is diversifying into healthcare services, showing its intent to expand beyond insurance. Despite its shares being down by 9.2%, there have been positive reactions from several asset management firms. Notably Raymond James and Bernstein maintained a 'buy rating' with target prices of $340 and $341, respectively. The company has also engaged new partnerships, notably with
Vori Health and
HOPCo, that aim to enhance patient outcomes. Numerous transactions have been noted lately such as Alliancebernstein L.P. and the United Services Automobile Association purchasing sizable shares of Humana Inc. On the flip side, despite winning TVH assets in a bankruptcy sale, certain cut points have been dragging the shares. Regardless,
HUM rebounded showing a promising valuation for investors. However, it is worth noting there have been recent drops followed by increases in the shares' performance. A development to keep an eye on is HUM's upswing of 19.2% since its last earnings report, along with an anticipation of beating earnings estimates. However, it recently lost a bid to reverse Medicare bonus cuts.
Humana HUM News Analytics from Mon, 10 Feb 2025 08:00:00 GMT to Sun, 14 Sep 2025 00:17:41 GMT -
Rating 5
- Innovation -3
- Information 7
- Rumor 1
